Telapristone (proposed trade names Proellex and Progenta) is an investigational selective progesterone receptor modulator tested for treatment of progesterone sensitive myomata. CDB-4124 was originally developed the National Institutes of Health and as of 2012 is in Phase II clinical trials for uterine fibroids and endometriosis. It also has some antiglucocorticoid activity.[citation needed]
This page contains content from the copyrighted Wikipedia article "Telapristone"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
